Clinical trial · Interventional
Robotic Dog Intervention on Emotional Well-Being and Quality of Life
Effectiveness and Feasibility of a Robotic Dog Intervention on Emotional Well-Being and Quality of Life in Pediatric Patients With Hematological Malignancies Undergoing HSCT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The hematopoietic stem cell transplantation (HSCT) process imposes a substantial psychological burden, leading to impaired emotional well-being due to intensive treatment, isolation, and immunosuppression. Patients often experience social withdrawal, loneliness, and loss of control, which may result in persistent anxiety, depressive symptoms, and reduced quality of life (QoL) if unaddressed. This study aims to evaluate the effectiveness, feasibility, and acceptability of an AI-powered robotic dog in improving emotional well-being and QoL in pediatric patients undergoing HSCT.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Emotional Well-being | — | UNRESOLVED | — |
| Pediatric Oncology | — | UNRESOLVED | — |
| Quality of Life | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| AIBO | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- NO_INTERVENTION
- label
- Standard care & Control Group Care
- description
- Participants in the control group will receive standard post-transplant inpatient care routinely provided in the HSCT unit. Standard care includes protective isolation procedures, restricted visitor access, routine clinical monitoring, and infection control practices during the inpatient transplantation period. Children are permitted to use personal electronic devices and other approved washable or disinfectable materials available within institutional infection control regulations. No structured psychosocial or technology-assisted intervention will be provided to the control group during the study period.
- type
- EXPERIMENTAL
- label
- Intervention Group (AIBO Group):
- description
- Participants assigned to the intervention group will receive standard post-transplant inpatient care in addition to a technology-assisted psychosocial support intervention during the inpatient isolation period following HSCT. The intervention will be implemented throughout the hospitalization period, and participants will be encouraged to engage with the device regularly during daily care routines. Baseline assessments will be performed within the first 24-48 hours after HSCT, and follow-up assessments will be conducted weekly for four weeks. Intervention adherence, feasibility indicators, and adverse events will be monitored throughout the study period. Infection control procedures will be applied according to institutional protocols.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 8 Years
- Maximum age
- 15 Years
Show eligibility criteria text
Inclusion Criteria: * Pediatric patients aged 8-15 years * Diagnosed with a hematological malignancy and undergoing hematopoietic stem cell transplantation * Hospitalized in a protective isolation room during the post-transplant inpatient period * Expected to remain hospitalized under isolation for approximately 30 days post-transplant * Able to understand and respond to Turkish-language self-report questionnaires * Clinically stable and deemed eligible for participation by the treating clinical team * Able to interact with the robotic dog at a basic functional level Exclusion Criteria: * Severe cognitive impairment or neurodevelopmental conditions preventing meaningful interaction or self-report * Acute neurological conditions, delirium, or severe psychiatric crisis (e.g., acute agitation, suicidal ideation) * Requirement for intensive care, invasive ventilation, or a clinically unstable condition * Severe visual, hearing, or motor impairments that prevent interaction with the robotic dog * Additional infection control restrictions prevent the placement or use of the robotic dog in the isolation room * Anticipated early discharge, transfer, or inability to complete follow-up assessments * Severe fear, intolerance, or refusal to interact with robotic or electronic devices
References
Publications (0)
Data not yet available